TheraRadar

Vanda

Pre-Approval PRO BETA
67
Total Trials
26
Phase 3
22
Phase 2
16
Recruiting
654
Score

Pipeline by Phase

Phase 3
26
Phase 2
22
Phase 1
21

Therapeutic Focus

Schizophrenia Healthy Volunteers Motion Sickness Bipolar I Disorder Healthy

Clinical Trials (67)

NCT07446439 Phase 3 RECRUITING

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Started: 3/27/2026

NCT07221578 Phase 3 RECRUITING

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

Started: 9/22/2025

NCT06830044 Phase 3 RECRUITING

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Started: 3/3/2025

NCT07362017 Phase 3 RECRUITING

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Started: 2/17/2026

NCT06961968 Phase 3 RECRUITING

Randomized Withdrawal Study in Patients With Schizophrenia

Started: 5/14/2025

NCT04652882 Phase 3 RECRUITING

Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

Started: 12/9/2020

NCT06953869 Phase 3 RECRUITING

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Started: 4/21/2025

NCT06836557 Phase 3 RECRUITING

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

Started: 1/9/2024

NCT06701396 Phase 3 RECRUITING

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

Started: 10/8/2024

NCT06138613 Phase 3 ACTIVE NOT RECRUITING

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Started: 2/27/2023

NCT05366855 Phase 3 TERMINATED

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Started: 4/21/2022

NCT05352893 Phase 3 COMPLETED

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Started: 4/14/2022

NCT04028492 Phase 3 COMPLETED

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Started: 8/20/2019

NCT05903924 Phase 3 COMPLETED

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Started: 9/9/2023

NCT04327661 Phase 3 COMPLETED

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Started: 11/15/2021

NCT04140695 Phase 3 TERMINATED

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

Started: 10/21/2019

NCT03568331 Phase 3 COMPLETED

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

Started: 7/9/2018

NCT04819776 Phase 3 COMPLETED

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Started: 3/22/2021

NCT03373201 Phase 3 COMPLETED

Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia

Started: 10/16/2017

NCT01291511 Phase 3 COMPLETED

Relapse Prevention Study in Patients With Schizophrenia

Started: 2/1/2011

NCT04326426 Phase 3 ENROLLING BY INVITATION

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Started: 4/13/2020

NCT01429116 Phase 3 COMPLETED

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Started: 10/1/2011

NCT01163032 Phase 3 COMPLETED

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Started: 8/1/2010

NCT01430754 Phase 3 COMPLETED

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Started: 9/1/2011

NCT07090161 Phase 2 RECRUITING

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Started: 9/15/2025

NCT07179055 Phase 2 RECRUITING

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Started: 10/1/2025

NCT07065773 Phase 2 ACTIVE NOT RECRUITING

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

Started: 5/5/2025

NCT06804603 Phase 2 COMPLETED

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Started: 2/25/2025

NCT04856917 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Started: 5/15/2021

NCT04697069 Phase 2 TERMINATED

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

Started: 5/4/2021

NCT04856930 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Started: 7/7/2021

NCT04697056 Phase 2 TERMINATED

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Started: 1/25/2021

NCT03619902 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

Started: 1/30/2019

NCT03633396 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Started: 5/20/2019

NCT04622345 Phase 2 COMPLETED

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Started: 11/21/2020

NCT03772340 Phase 2 COMPLETED

Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Started: 12/20/2018

NCT02970968 Phase 2 COMPLETED

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

Started: 11/1/2016

NCT02651714 Phase 2 COMPLETED

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Started: 1/19/2016

NCT02004041 Phase 2 COMPLETED

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

Started: 12/10/2013

NCT05344365 Phase 2 WITHDRAWN

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Started: 6/1/2022

NCT04800237 Phase 2 COMPLETED

Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety

Started: 2/23/2021

NCT02231008 Phase 2 COMPLETED

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

Started: 9/1/2015

NCT03291041 Phase 2 COMPLETED

A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder

Started: 7/1/2016

NCT01428661 Phase 2 COMPLETED

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

Started: 9/1/2011

NCT03838926 Phase 1 RECRUITING

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Started: 9/27/2018

NCT07223632 Phase 1 ACTIVE NOT RECRUITING

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

Started: 5/13/2025

NCT06494397 Phase 1 COMPLETED

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Started: 7/11/2024

NCT06803290 Phase 1 COMPLETED

Food Effect Study of VHX-896 in Healthy Volunteers

Started: 6/21/2022

NCT04849559 Phase 1 COMPLETED

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Started: 2/1/2021

NCT06323655 Phase 1 COMPLETED

Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

Started: 7/19/2018

NCT02776215 Phase 1 COMPLETED

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

Started: 10/4/2016

NCT05572281 Phase 1 COMPLETED

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Started: 5/18/2022

NCT04712734 Phase 1 COMPLETED

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Started: 1/13/2021

NCT04969211 Phase 1 COMPLETED

Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers

Started: 6/30/2021

NCT04127058 Phase 1 COMPLETED

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Started: 10/7/2019

NCT01495169 Phase 1 COMPLETED

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

Started: 10/1/2011

NCT02621385 Phase 1 COMPLETED

Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects

Started: 11/1/2015

NCT01919944 Phase 1 COMPLETED

Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

Started: 8/1/2013

NCT01271387 Phase 1 COMPLETED

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Started: 1/1/2011

NCT01402076 Phase 1 COMPLETED

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

Started: 8/1/2011

NCT01526746 Phase 1 COMPLETED

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Started: 2/1/2012

NCT01540500 Phase 1 COMPLETED

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

Started: 2/1/2012

NCT01637636 Phase 1 COMPLETED

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Started: 6/1/2012

NCT01578057 Phase 1 COMPLETED

Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol

Started: 4/1/2012

NCT01477619 Phase 1 COMPLETED

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Started: 11/1/2011

NCT05648591 Phase 4 RECRUITING

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Started: 5/24/2023

NCT02130999 Phase 4 COMPLETED

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Started: 5/1/2014

Drug Candidates

Tradipitant VQW-765 Double-blind 200 mg imsidolimab Open-label 200 mg imsidolimab Imsidolimab 750 mg IV/200 mg SC Trichostatin A iloperidone Milsaperidone Ponesimod Tasimelteon
Activity Status: Active
Last Trial Started: 3/27/2026
Last Trial Ended: 10/6/2025
Trials (12 months): 5
Completed Trials: 45
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.